Immunovia AB (IMMNOV) Price & Analysis

Q: What was Immunovia AB’s price range in the past 12 months?

Immunovia AB lowest stock price was kr0.17 and its highest was kr0.75 in the past 12 months.

Q: What is Immunovia AB’s market cap?

Immunovia AB’s market cap is kr127.13M.

Q: When is Immunovia AB’s upcoming earnings report date?

Immunovia AB’s upcoming earnings report date is Feb 24, 2026 which is in 10 days.

Q: How were Immunovia AB’s earnings last quarter?

Immunovia AB released its earnings results on Nov 26, 2025. The company reported -kr0.078 earnings per share for the quarter, missing the consensus estimate of -kr0.047 by -kr0.031.

Q: Is Immunovia AB overvalued?

According to Wall Street analysts Immunovia AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: Does Immunovia AB pay dividends?

Immunovia AB does not currently pay dividends.

Q: What is Immunovia AB’s EPS estimate?

Immunovia AB’s EPS estimate is -0.04.

Q: How many shares outstanding does Immunovia AB have?

Immunovia AB has 672,666,900 shares outstanding.

Q: What happened to Immunovia AB’s price movement after its last earnings report?

Immunovia AB reported an EPS of -kr0.078 in its last earnings report, missing expectations of -kr0.047. Following the earnings report the stock price went up 7.813%.

Q: Which hedge fund is a major shareholder of Immunovia AB?

Currently, no hedge funds are holding shares in SE:IMMNOV

Compare

4 Followers

IMMNOV Stock Chart & Stats

kr0.23

-kr0.02(-4.98%)

At close: Mar 06 4:00 PM EST

kr0.23

-kr0.02(-4.98%)

Day’s Range― - ―

52-Week Rangekr0.18 - kr0.75

Previous CloseN/A

Volume868.16K

Average Volume (3M)5.10M

Market Cap

kr127.13M

Enterprise Valuekr48.77M

Total Cash (Recent Filing)kr26.57M

Total Debt (Recent Filing)kr20.37M

Price to Earnings (P/E)―

Beta-0.31

Next Earnings

Feb 24, 2026

EPS Estimate

-0.04

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.08

Shares Outstanding672,666,900

10 Day Avg. Volume6,199,351

30 Day Avg. Volume5,096,607

Financial Highlights & Ratios

PEG Ratio<0.01

Price to Book (P/B)3.01

Price to Sales (P/S)37.67

P/FCF Ratio-0.36

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Immunovia AB News

Immunovia to Outline PancreaSure Commercial Strategy at Aktiespararna Life Science Event

An announcement from Immunovia AB ( ($SE:IMMNOV) ) is now available. Immunovia AB will present its commercial strategy...

22d ago

Immunovia Drops Reverse Share Split Plan After Shareholder Pushback

Immunovia AB ( ($SE:IMMNOV) ) just unveiled an update. Immunovia AB has withdrawn its proposal for a reverse...

25d ago

Immunovia Wins California Approval for PancreaSure, Advancing US Pancreatic Cancer Test Rollout

The latest announcement is out from Immunovia AB ( ($SE:IMMNOV) ). Immunovia AB, a Nasdaq Stockholm–listed pancreatic cancer...

26d ago

Immunovia Names 2026 Nomination Committee to Support U.S.-Focused Commercial Push

Immunovia AB ( ($SE:IMMNOV) ) has shared an announcement. Immunovia AB has appointed its 2026 Nomination Committee, in...

30d ago

Immunovia’s PancreaSure Validation Study Published, Bolstering Early Pancreatic Cancer Test

Immunovia AB ( ($SE:IMMNOV) ) has issued an update. Immunovia has announced that its analytical validation study of...

2M ago

Immunovia Proposes 1:100 Reverse Share Split Ahead of 2026 Meeting

An announcement from Immunovia AB ( ($SE:IMMNOV) ) is now available. Immunovia AB has proposed a reverse share...

2M ago

Immunovia AB Announces EGM for Reverse Share Split and Articles Amendment

Immunovia AB ( ($SE:IMMNOV) ) has provided an announcement. Immunovia AB has announced an Extraordinary General Meeting (EGM)...

2M ago

Immunovia AB Expands Share Count to Bolster Market Position

The latest update is out from Immunovia AB ( ($SE:IMMNOV) ). Immunovia AB has increased its number of...

3M ago

Immunovia AB’s Earnings Call: Progress and Challenges

Immunovia AB (($SE:IMMNOV)) has held its Q3 earnings call. Read on for the main highlights of the call....

3M ago

Immunovia AB Reports Q3 2025 Earnings and Strategic Progress

Immunovia AB ( ($IMMVF) ) has released its Q3 earnings. Here is a breakdown of the information Immunovia...

3M ago

Onconetix’s Proteomedix licenses manufacturing IP to Immunovia

Onconetix (ONCO) announced that its wholly owned subsidiary, Proteomedix has signed a licensing agreement, with Immunovia (IMMVF), a...

5M ago

ONCO

Immunovia provides further data from VERIFI study of pancreatic cancer test

Immunovia (IMMVF) announced additional results from the VERIFI study of its next-generation pancreatic cancer test. Immunovia’s next-generation test...

11M ago

IMMNOV FAQ

What was Immunovia AB’s price range in the past 12 months?

Immunovia AB lowest stock price was kr0.17 and its highest was kr0.75 in the past 12 months.

What is Immunovia AB’s market cap?

Immunovia AB’s market cap is kr127.13M.

When is Immunovia AB’s upcoming earnings report date?

Immunovia AB’s upcoming earnings report date is Feb 24, 2026 which is in 10 days.

How were Immunovia AB’s earnings last quarter?

Immunovia AB released its earnings results on Nov 26, 2025. The company reported -kr0.078 earnings per share for the quarter, missing the consensus estimate of -kr0.047 by -kr0.031.

Is Immunovia AB overvalued?

According to Wall Street analysts Immunovia AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Immunovia AB pay dividends?

Immunovia AB does not currently pay dividends.

What is Immunovia AB’s EPS estimate?

Immunovia AB’s EPS estimate is -0.04.

How many shares outstanding does Immunovia AB have?

Immunovia AB has 672,666,900 shares outstanding.

What happened to Immunovia AB’s price movement after its last earnings report?

Immunovia AB reported an EPS of -kr0.078 in its last earnings report, missing expectations of -kr0.047. Following the earnings report the stock price went up 7.813%.

Which hedge fund is a major shareholder of Immunovia AB?

Currently, no hedge funds are holding shares in SE:IMMNOV

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Immunovia AB

Immunovia AB (publ), a diagnostic company, develops and commercializes blood tests in Sweden and internationally. The company's product includes IMMray PanCan-d, a blood-based test for the early detection of pancreatic cancer. It also develops research projects for lung cancer. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.

Immunovia AB (IMMNOV) Earnings & Revenues

Historic Earnings Reports

IMMNOV Company Deck

IMMNOV Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reveals significant progress in Immunovia's commercial transition and positive initial market response to PancreaSure, alongside key milestones in reimbursement rate setting. However, uncertainties remain regarding coverage and revenue timelines.View all SE:IMMNOV earnings summaries